Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZHUO5)

Drug Name
Phenylephrine Drug Info
Synonyms
Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
Therapeutic ClassOphthalmologicals
Cross-matching ID
PubChem CID
6041
ChEBI ID
CHEMBL1215
CAS Number
CAS 61-76-7
TTD Drug ID
D0O6IU
VARIDT Drug ID
DR01201
ACDINA Drug ID
D00528

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.26 0.00e+0 101/150 (67.33%) LSM5;HNRNPA3;ACIN1;...
Biosynthesis of unsaturated fatty acids 1.85 1.40e-2 21/27 (77.78%) FADS1;ELOVL2;FADS2;...
Fanconi anemia pathway 1.79 2.57e-2 36/54 (66.67%) HES1;TELO2;FANCG;...
Legionellosis 1.75 4.03e-2 51/57 (89.47%) CXCL2;EEF1A2;C3;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.60 4.97e-2 79/89 (88.76%) MAPK3;PDCD1;EGF;...
Th17 cell differentiation -1.63 4.57e-2 95/107 (88.79%) MAPK11;FOS;IL22;...
Other glycan degradation -1.63 4.56e-2 13/18 (72.22%) MAN2B1;HEXA;AGA;...
Human T-cell leukemia virus 1 infection -1.64 4.32e-2 197/219 (89.95%) CCNE1;FOS;CDKN2B;...
VEGF signaling pathway -1.67 3.04e-2 50/59 (84.75%) MAP2K1;MAPKAPK3;MAPK1;...
Metabolism of xenobiotics by cytochrome P450 -1.67 3.01e-2 49/77 (63.64%) CYP1A2;SULT2A1;EPHX1;...
Renin secretion -1.69 2.58e-2 61/69 (88.41%) CALML3;PDE1A;PLCB4;...
Toll-like receptor signaling pathway -1.69 2.38e-2 94/104 (90.38%) MAP2K6;CD40;TLR5;...
Human immunodeficiency virus 1 infection -1.71 2.21e-2 189/212 (89.15%) PTK2;CALML3;PRKCB;...
Apelin signaling pathway -1.73 1.91e-2 117/137 (85.4%) KLF2;PLCB4;GNG5;...
Mitophagy -1.73 1.70e-2 56/68 (82.35%) GABARAPL1;CSNK2B;HIF1A;...
Rheumatoid arthritis -1.73 1.79e-2 78/93 (83.87%) IL23A;TEK;CD28;...
Pancreatic cancer -1.73 1.89e-2 75/76 (98.68%) BCL2L1;STAT1;KRAS;...
Intestinal immune network for IgA production -1.75 1.86e-2 38/48 (79.17%) PIGR;IL4;IL10;...
Collecting duct acid secretion -1.75 1.82e-2 22/27 (81.48%) ATP6V1B2;SLC4A1;ATP6V1G1;...
Folate biosynthesis -1.75 1.86e-2 23/26 (88.46%) GCH1;SPR;GGH;...
Inflammatory bowel disease -1.76 2.00e-2 58/65 (89.23%) IL22;STAT1;IL4;...
Osteoclast differentiation -1.76 1.96e-2 117/127 (92.13%) MITF;MAPK10;IKBKG;...
C-type lectin receptor signaling pathway -1.79 1.82e-2 93/104 (89.42%) STAT1;KRAS;MAPK10;...
Natural killer cell mediated cytotoxicity -1.80 1.88e-2 99/131 (75.57%) MAPK1;HLA-C;ICAM1;...
Th1 and Th2 cell differentiation -1.82 1.46e-2 80/92 (86.96%) MAPK8;DLL3;MAPK11;...
Human cytomegalovirus infection -1.83 1.62e-2 201/225 (89.33%) PTK2;CALML3;PRKCB;...
Primary immunodeficiency -1.85 1.06e-2 33/38 (86.84%) CD40;ZAP70;TAP1;...
Asthma -1.95 3.47e-3 25/31 (80.65%) HLA-DQA1;IL13;CD40LG;...
Antigen processing and presentation -2.01 2.03e-3 60/78 (76.92%) CANX;CIITA;HSPA2;...
T cell receptor signaling pathway -2.01 2.43e-3 93/104 (89.42%) CD40LG;RHOA;DLG1;...
Allograft rejection -2.06 0.00e+0 32/38 (84.21%) IL4;IL10;IL2;...
Autoimmune thyroid disease -2.13 0.00e+0 46/53 (86.79%) IL4;IL10;IL2;...
Graft-versus-host disease -2.25 0.00e+0 32/42 (76.19%) CD28;HLA-C;HLA-DOB;...
Type I diabetes mellitus -2.26 0.00e+0 38/43 (88.37%) CD28;HLA-C;HLA-DOB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 100uM 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.03uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.08uM - 100uM 3H, 24H, 48H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 20uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H